Inhibrx Biosciences (INBX) Q3 2026

Q3 net loss was $38.7M vs. $35.3M, and loss per share missed the $2.36 third-party consensus.

Inhibrx Biosciences · Q3 2026 · Published Nov 13, 2026 · By DeepCell AI · Sources

Inhibrx Biosciences (INBX) Q3 2026


Quarter ended September 30, 2026

For information only, not investment advice. No rating or price target.

1 · Inhibrx (INBX) Q3 2026 earnings review

Q3 net loss was $38.7M vs. $35.3M, and loss per share missed the $2.36 third-party consensus


  1. 1.Revenue of $2.0M was a Pfizer license upfront payment; none in Q3 2025
  2. 2.Loss per share of $2.46 was $0.10 worse than the third-party TipRanks consensus
  3. 3.R&D expense fell to $26.0M and G&A expense rose to $7.8M
  4. 4.Cash was $199.5M against $275.0M of loan principal; a $150M ATM was filed
  5. 5.Shares closed at $83.30 on Nov 13; after-hours $81.18 is not a close
2

2 · Executive summary

Q3 loss per share of $2.46 missed the third-party TipRanks consensus of $2.36 by $0.10


Q3 2026 results vs. third-party consensus (TipRanks / The Fly, Nov 13, 2026)

MetricActualConsensusVarianceResult
Q3 loss per share ($)-$2.46-$2.36-$0.10 / -4.2%Miss

Share price: Nov 12 and Nov 13 closes, and Nov 13 after-hours (not a close)

INBX (Nasdaq)Nov 12 closeNov 13 closeClose changeAfter-hours, 4:30 PM ETAfter-hours vs close
INBX$87.75$83.30-5.1%$81.18-2.5%
3

3 · Q3 results vs. consensus

Inhibrx gave no financial guidance, and it listed a Nov 19-20 Ewing sarcoma update and mid-2027 readouts


Management commentary and milestones in the Q3 2026 release (Nov 13, 2026)

ProgramMilestoneTimingStatus
Ozekibart, Ewing sarcomaUpdated Phase 1/2 results with irinotecan and temozolomideCTOS meeting, Nov 19-20, 2026Scheduled
Ozekibart, chondrosarcomaCommercial readiness in line with the BLA review timelineFDA accepted BLA filing in June 2026Under review
Ordastobart, HNSCCPhase 2 expansion, about 50 more HPV-positive patientsInitial readout around mid-2027Enrolling
Ordastobart, NSCLCInitial perioperative Phase 1/2 resultsMid-2027Expected
Financial guidanceNone givenNone givenn.a.
4

4 · Pipeline milestones and outlook

Operating loss narrowed 6.1% to $31.7M, but other expense raised the net loss to $38.7M


  1. License revenueRevenue was $2.0M from a non-exclusive Pfizer patent license; Q3 2025 had none.
  2. ExpensesR&D expense fell $2.6M and G&A expense rose $2.5M YoY.
  3. Interest costOther expense rose $5.6M to $7.0M on the larger loan.

Key figures (U.S. GAAP)

$M unless notedQ3 2025Q3 2026YoY
Revenue$0.0M$2.0Mn.a.
Loss from operations($33.8M)($31.7M)-6.1%
Total other expense($1.4M)($7.0M)+384.6%
Net loss($35.3M)($38.7M)+9.9%
Loss per share ($)-$2.28-$2.46+7.9%
5

5 · Q3 key financials

Net loss widened to $38.7M from $35.3M, as other expense rose $5.6M


Operating loss and other expense

$M, Q3 2025 vs Q3 2026

Net loss rose $3.5M. Interest expense was $8.8M, from $3.2M, on $275.0M of loan principal against $100.0M.
6

6 · Net loss drivers

R&D expense fell 9.0% to $26.0M, while G&A expense rose 47.2% to $7.8M


  1. R&D expenseClinical trial expense fell $3.2M after enrollment completed in the chondrosarcoma trial; contract manufacturing rose $1.9M for the BLA, as stated.
  2. HeadcountPersonnel-related R&D expense fell on reduced headcount, as stated.
  3. G&A expensePre-commercialization spending on market access, launch and communication materials raised G&A expense, as stated.

Operating expenses

$MQ3 2025Q3 2026YoY
Research and development$28.5M$26.0M-9.0%
General and administrative$5.3M$7.8M+47.2%
Total operating expenses$33.8M$33.7M-0.2%
7

7 · Operating expense drivers

R&D expense fell $2.6M while G&A expense rose $2.5M YoY


R&D and G&A expense

$M, Q3 2025 vs Q3 2026

Total operating expenses were $33.7M, nearly flat from $33.8M. Nine-month R&D expense was $75.1M, from $87.7M.
8

8 · R&D and G&A expense

Cash rose to $199.5M as long-term debt rose to $276.7M


Cash and long-term debt, net

$M, Dec 31, 2025 and Sep 30, 2026

Loan principal was $275.0M. Cash less loan principal was ($75.5M), a DeepCell calculation. Inhibrx says cash covers operations for at least 12 months.
9

9 · Cash and debt

Nine-month operating cash use was $102.5M, funded by $177.8M of financing


  1. Operating cash useOperating cash flow was ($102.5M), against net loss of $108.8M.
  2. Debt financingDebt proceeds were $175.0M, from $100.0M a year earlier.
  3. Interest paidCash paid for interest was $12.4M, from $6.4M.

Cash flow, nine months

$M9M 20259M 2026
Operating cash flow($99.7M)($102.5M)
Financing cash flow$100.2M$177.8M
Net change in cash$0.5M$75.2M
Cash at period end$153.1M$199.5M
Stock-based compensation$8.4M$9.1M
10

10 · Cash flow and financing

Debt service, equity funding and the BLA decision are the main watch items


Indicator
What to watch
Implication
Latest reading
Debt service
Interest-only payments end in February 2028
Principal repayments begin in March 2028
Minimum $366.8M due
Equity funding
An at-the-market program was filed on Nov 13
Sales would add shares
Up to $150M
BLA decision
Ozekibart BLA is under FDA review
Approval is not assured
Cash $199.5M
11

11 · Key risks to the outlook

Appendix: Oxford loan facility terms


ClaimEvidenceCalculation
Loan principal outstanding$275.0MFrom $100.0M a year ago
Interest rate5.61% plus SOFRSOFR floor 4.34%
Maturity and repaymentJan 1, 2030Interest-only to Feb 2028
Final payment$24.8M9.0% of principal
Further Term D loansUp to $225MLender discretion
12

12 · Appendix: Loan terms

Appendix: Pfizer license agreement and revenue


ClaimEvidenceCalculation
Q3 2026 revenue$2.0MUpfront, Aug 24, 2026 license
Nine-month revenue$2.0MFrom $1.3M in 2025
Milestones per productUp to $36.5MDevelopment, regulatory
Milestones, three productsUp to $109.5MRoyalties up to 1%
Accumulated deficit$355.0MAt Sep 30, 2026
13

13 · Appendix: Pfizer license

14 · Appendix: Nine-month results

Appendix: income statement detail


Operating results

$M unless notedQ3 2025Q3 2026YoY
Revenue$0.0M$2.0Mn.a.
Research and development$28.5M$26.0M-9.0%
General and administrative$5.3M$7.8M+47.2%
Loss from operations($33.8M)($31.7M)-6.1%

Below the operating line

$M unless notedQ3 2025Q3 2026YoY
Total other expense($1.4M)($7.0M)+384.6%
Net loss($35.3M)($38.7M)+9.9%
Loss per share ($)-$2.28-$2.46+7.9%
15

15 · Appendix: Income statement

Appendix: sources


  • Results release, Q3 2026 (Form 8-K, Ex. 99.1, accession 0002007919-26-000057, Nov 13, 2026; EDGAR accepted 4:08 PM ET) — https://www.sec.gov/Archives/edgar/data/2007919/000200791926000057/exhibit99109302026.htm
  • Same release on PR Newswire, Nov 13, 2026, 4:02 PM ET — https://www.prnewswire.com/news-releases/inhibrx-reports-third-quarter-2026-financial-results-302939250.html
  • Form 10-Q for the quarter ended Sep 30, 2026 (accession 0002007919-26-000059, Nov 13, 2026; EDGAR accepted 4:12 PM ET) — https://www.sec.gov/Archives/edgar/data/2007919/000200791926000059/inhibrx-20260930.htm
  • Form S-3ASR with at-the-market sales agreement (accession 0002007919-26-000061, Nov 13, 2026, 4:25 PM ET) — https://www.sec.gov/Archives/edgar/data/2007919/000200791926000061/inbxs-3asrxnovember2026atm.htm
  • Consensus: TipRanks / The Fly headline, Nov 13, 2026 — https://www.tipranks.com/news/the-fly/inhibrx-reports-q3-eps-2-46-consensus-2-36-thefly-news; cross-check: Yahoo Finance analysis page (average -$2.36, 2 analysts) — https://finance.yahoo.com/quote/INBX/analysis/
  • Share price: CNBC INBX quote, Nov 12, 2026 close $87.75, Nov 13, 2026 close $83.30, after-hours last $81.18 at 4:30 PM ET (not a close) — https://www.cnbc.com/quotes/INBX
  • Inhibrx reports under U.S. GAAP in U.S. dollars. Release figures in $ thousands were converted to $ millions.
16

16 · Sources

Important disclosures and disclaimer


For information only. This presentation is provided for information only. It is not investment, legal, tax or accounting advice, and it is not an offer, or a solicitation of an offer, to buy or sell any security.

No recommendation. It carries no rating, price target or buy, sell or hold view, and it was prepared without regard to any reader’s investment objectives, financial situation or needs.

Sources and accuracy. Company figures come from Inhibrx Biosciences, Inc.’s Q3 2026 results release furnished on Form 8-K, its Form 10-Q and its Form S-3ASR, all dated November 13, 2026. The consensus estimate (TipRanks / The Fly) and share prices (CNBC) are third-party data, credited on the sources page. Other data vendors show different consensus figures. We have not independently verified third-party data.

Basis of presentation. Figures are U.S. GAAP, in U.S. dollars, for the three months ended September 30, 2026 and September 30, 2025, unless labelled nine months.

Forward-looking statements. Company milestones, consensus estimates and the watch items in this deck are forward-looking and may not be achieved. Readers should check the figures against the original filings.

Date of analysis. Share prices are the CNBC regular-session closes on November 12 and November 13, 2026. The after-hours price at 4:30 PM ET on November 13, 2026 is the last trade after the close, not a close.

17

17 · Disclosures

Share this review

Send the link: it opens with the picture below, and every number on the page still opens its formula and source. The picture is free to download and share.

More earnings reviews

All earnings reviews
  • KT Corp · Q3 2026

    KT Corp (KT) Q3 2026

    Q3 operating income fell 6.1% YoY to KRW 505.3B, and net income fell 17.5%, as stated.

    Nov 14, 202613 slides

  • LG Display · Q3 2026

    LG Display (LPL) Q3 2026

    Q3 operating income fell 42% YoY to KRW 250.6B, while net income rose to KRW 755.6B, partly on FX-related gains.

    Nov 14, 202613 slides

  • Boston Omaha · Q3 2026

    Boston Omaha (BOC) Q3 2026

    Q3 net loss narrowed to $0.2M from $2.6M, and the buyback program rose to $85M.

    Nov 13, 202613 slides

  • Sumitomo Mitsui Financial Group · H1 FY2027

    Sumitomo Mitsui Financial (SMFG) H1 FY3/27

    H1 profit rose 7.5% to JPY 1.00T, and SMFG raised its full-year forecast to JPY 1.9T.

    Nov 13, 202616 slides

  • Mitsubishi UFJ Financial Group · Q2 FY2026

    Mitsubishi UFJ (MUFG) Q2 FY2026

    H1 profit rose 26.1% to JPY 1,630.8B, as stated, and MUFG raised its FY2026 profit target to JPY 2.80T.

    Nov 13, 202617 slides